| Date | Time | Source | Headline | Symbol | Company |
| 11/17/2023 | 6:02AM | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:IDYA | IDEAYA Biosciences Inc |
| 11/07/2023 | 5:47PM | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:IDYA | IDEAYA Biosciences Inc |
| 11/07/2023 | 4:01PM | Edgar (US Regulatory) | Form 10-Q - Quarterly report [Sections 13 or 15(d)] | NASDAQ:IDYA | IDEAYA Biosciences Inc |
| 11/07/2023 | 6:01AM | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:IDYA | IDEAYA Biosciences Inc |
| 11/07/2023 | 6:00AM | PR Newswire (US) | IDEAYA Biosciences, Inc. Reports Third Quarter 2023 Financial Results and Provides Business Update | NASDAQ:IDYA | IDEAYA Biosciences Inc |
| 11/01/2023 | 6:00AM | PR Newswire (US) | IDEAYA Biosciences Announces Plans for Investor R&D Day and Participation in Jefferies London Healthcare Conference | NASDAQ:IDYA | IDEAYA Biosciences Inc |
| 10/27/2023 | 4:23PM | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:IDYA | IDEAYA Biosciences Inc |
| 10/27/2023 | 4:02PM | PR Newswire (US) | IDEAYA Announces Closing of Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares | NASDAQ:IDYA | IDEAYA Biosciences Inc |
| 10/27/2023 | 6:00AM | PR Newswire (US) | IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | NASDAQ:IDYA | IDEAYA Biosciences Inc |
| 10/25/2023 | 9:45PM | Edgar (US Regulatory) | Form 424B5 - Prospectus [Rule 424(b)(5)] | NASDAQ:IDYA | IDEAYA Biosciences Inc |
| 10/24/2023 | 10:15PM | PR Newswire (US) | IDEAYA Announces Pricing of Public Offering | NASDAQ:IDYA | IDEAYA Biosciences Inc |
| 10/24/2023 | 5:26PM | Edgar (US Regulatory) | Form 424B5 - Prospectus [Rule 424(b)(5)] | NASDAQ:IDYA | IDEAYA Biosciences Inc |
| 10/24/2023 | 4:21PM | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:IDYA | IDEAYA Biosciences Inc |
| 10/24/2023 | 4:07PM | PR Newswire (US) | IDEAYA Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants | NASDAQ:IDYA | IDEAYA Biosciences Inc |
| 10/23/2023 | 8:09AM | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:IDYA | IDEAYA Biosciences Inc |
| 10/23/2023 | 6:00AM | PR Newswire (US) | IDEAYA Announces Top-Line Phase 2 Results at ESMO 2023 of Darovasertib and Crizotinib Combo in MUM, and Clinical Efficacy Updates for Neoadjuvant UM, GNAQ/11 Cutaneous Melanoma, and Synthetic Lethality Pipeline | NASDAQ:IDYA | IDEAYA Biosciences Inc |
| 10/17/2023 | 6:00AM | PR Newswire (US) | IDEAYA Biosciences Announces Proffered Paper Oral Presentation at ESMO 2023 for Phase 2 Clinical Data Update for Darovasertib and Crizotinib Combination in Metastatic Uveal Melanoma | NASDAQ:IDYA | IDEAYA Biosciences Inc |
| 10/16/2023 | 6:00AM | PR Newswire (US) | IDEAYA Biosciences Announces Phase 2 Expansion of Darovasertib and Crizotinib Combination in GNAQ/11 Metastatic Cutaneous Melanoma | NASDAQ:IDYA | IDEAYA Biosciences Inc |
| 10/09/2023 | 6:00AM | PR Newswire (US) | IDEAYA Biosciences Announces Development Candidate Nomination of a Werner Helicase Inhibitor in Collaboration with GSK and Investor R&D Day | NASDAQ:IDYA | IDEAYA Biosciences Inc |
| 10/06/2023 | 6:00AM | PR Newswire (US) | IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | NASDAQ:IDYA | IDEAYA Biosciences Inc |
| 09/27/2023 | 6:43AM | Dow Jones News | IDEAYA Biosciences Gets Fast-Track Designation for IDE161 for Breast Cancer | NASDAQ:IDYA | IDEAYA Biosciences Inc |
| 09/27/2023 | 6:00AM | PR Newswire (US) | IDEAYA Biosciences Receives Fast Track Designation for IDE161 in a Second Indication for the Treatment of Pretreated, Advanced or Metastatic HR+, Her2-, BRCA1/2 mutant Breast Cancer | NASDAQ:IDYA | IDEAYA Biosciences Inc |
| 09/26/2023 | 6:42AM | Dow Jones News | IDEAYA Biosciences Gets FDA Fast-Track Designation for IDE161 in Ovarian Cancer | NASDAQ:IDYA | IDEAYA Biosciences Inc |
| 09/26/2023 | 6:05AM | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:IDYA | IDEAYA Biosciences Inc |
| 09/26/2023 | 6:00AM | PR Newswire (US) | IDEAYA Receives Fast Track Designation for Potential First-in-Class PARG Inhibitor, IDE161, for Treatment of Pretreated, Platinum-Resistant Advanced or Metastatic Ovarian Cancer Patients having tumors with BRCA1/2 Mutations | NASDAQ:IDYA | IDEAYA Biosciences Inc |
| 09/14/2023 | 5:23PM | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:IDYA | IDEAYA Biosciences Inc |
| 09/11/2023 | 6:00AM | PR Newswire (US) | IDEAYA Announces Phase 1 Expansion and Preliminary Clinical Proof-of-Concept for Potential First-in-Class PARG Inhibitor IDE161 in HRD Solid Tumors | NASDAQ:IDYA | IDEAYA Biosciences Inc |
| 09/06/2023 | 6:37PM | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:IDYA | IDEAYA Biosciences Inc |
| 09/06/2023 | 6:36PM | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:IDYA | IDEAYA Biosciences Inc |
| 09/05/2023 | 6:00AM | PR Newswire (US) | IDEAYA Biosciences to Participate in Upcoming September 2023 Investor Relations Events | NASDAQ:IDYA | IDEAYA Biosciences Inc |